Sociedad Americana de Hirudoterapia

Bacterial Community of the Digestive Tract of the European Medicinal Leech (Hirudo verbana) from the Danube River

Microbiome study published in Microbial Ecology (2019)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaSeguridad y control de infeccionesNeupane S et al. · Microbial Ecology, 2019

Abstract

The digestive tract of medicinal leeches from commercial suppliers has been investigated previously and comprises of a relatively simple bacterial community. However, the microbiome of medicinal leeches collected directly from the natural habitat has not been examined. In this study, we characterized the bacterial community in the digestive tract (anterior crop, posterior crop, and intestine) of the European medicinal leech, Hirudo verbana, collected from the Danube river using culture-independent and culture-dependent approaches. Culture-independent approach confirmed that the digestive tract of H. verbana carries a relatively simple bacterial community with species richness in the individual samples ranging from 43 to164. The dominant bacterial taxon was Mucinivorans sp. (49.7% of total reads), followed by Aeromonas sp. (18.7% of total reads). Several low abundance taxa, new for H. verbana, such as Phreatobacter, Taibaiella, Fluviicola, Aquabacterium, Burkholderia, Hydrogenophaga, Wolinella, and unidentified Chitinophagia, were also detected. The aerobic culturing approach showed Aeromonas veronii (Proteobacteria), the known leech symbiont, as the most dominant taxon followed by several Pseudomonas and Acidovorax spp. No significant differences in the bacterial community composition were detected among different parts of the digestive tract of individual leeches. However, the overall composition of the bacterial community among individual specimen varied significantly and this is possibly due to differences in leech age, feeding status, and blood source. Our results showed that the core bacterial community of H. verbana collected from the natural habitat is similar to that reported from the digestive tract of commercially supplied leeches maintained in the laboratory.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsBacteriaGastrointestinal MicrobiomeGastrointestinal TractLeechesRNA, BacterialRNA, Ribosomal, 16SRiversRomania

Resumen

16S rDNA analysis of wild Hirudo verbana from the Danube River confirmed the core microbiome of Mucinivorans (49.7%) and Aeromonas (18.7%), with newly detected low-abundance taxa (Phreatobacter, Taibaiella, Fluviicola, etc.) and similar composition to commercially supplied leeches.

Por qué esto importa para la hirudoterapia

This study characterized the bacterial community in the digestive tract (anterior crop, posterior crop, intestine) of European medicinal leeches (Hirudo verbana) collected from the Danube River, using culture-independent and culture-dependent approaches. Mucinivorans sp. (49.7% of reads) and Aeromonas sp. (18.7%) dominated, with several low-abundance taxa newly detected; no significant differences were found among gut regions within individuals, though composition varied among specimens, possibly due to age, feeding status, or blood source. For ASH, this is relevant to understanding the microbiome of wild-caught medicinal leeches used in research and therapy. Caveat: the study is ecological and microbiological only, with no analysis of anticoagulants or salivary secretion, and thus has indirect relevance to hirudotherapy per se.

Citación

Bacterial Community of the Digestive Tract of the European Medicinal Leech (Hirudo verbana) from the Danube River.

Neupane S et al. · Microbial Ecology, 2019

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.